Home » FDA Rejects Able's Proposal; Firm Decides to Sell Business
FDA Rejects Able's Proposal; Firm Decides to Sell Business
August 23, 2005
The saga of troubled generic drugmaker Able Laboratories took yet another turn this month when the company said it intends to sell its assets — a move sparked by the FDA’s rejection of a consent
decree proposal that would have allowed the firm to relaunch its withdrawn drug products without having to resubmit abbreviated new drug applications (ANDAs).